October 08, 2019 01:15 ET | Source: Novartis International AG In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients[1],[2] Beovu demonstrated greater reductions in central subfield thickness (CST, a key indicator of fluid in the… Read More »
Professor Pravin U. Dugel, MD Pravin Dugel, Clinical Professor at the Roski Eye Institute, University of Southern California, USA, provides his expert insight into key data presented at EURETINA 2019 and discusses the latest developments in imaging and anti-VEGF agents mean for optimizing outcomes for patients with nAMD. Clinical Spotlight Why retinal fluid is important… Read More »
“Overall, the improvements to date represent a clear signal of efficacy in a patient population where inexorable disease progression is the norm,” the company said Clinical update and conference presentations “Clear efficacy signal” in Phase 2a study of hRPC cell therapy in retinitis pigmentosa ReNeuron Group plc (AIM: RENE), a global leader in the development… Read More »
American Vision Partners (“AVP”), one of the largest and fastest-growing eye care physician practice management organizations in the nation, announced the completion of a strategic partnership with Retinal Consultants of Arizona (“RCA”), the largest retina provider in the Southwest. This partnership creates the fourth largest retina practice in the nation. Retinal Consultants of Arizona will… Read More »
Eric D. Donnenfeld, M.D., an internationally recognized expert and pioneer in refractive, cornea and cataract surgery Ramin Tadayoni, M.D., Ph.D., renowned professor and ophthalmologist in the diagnosis and treatment of retinal diseases, retinovitreal surgery and ophthalmic imaging Lausanne, Switzerland, September 17, 2019 – Oculis S.A., a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments for… Read More »
Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME Immediate onset of action – starting from Day 1 with increasing average improvement in Best Corrected Visual Acuity (BCVA) of up to 7.5 letters at Day 14 following a single injection of THR-149. Prolonged durability… Read More »
Watch the Financing Retinal Innovation panel at Ophthalmology Innovation Summit @ ASRS 2019. The panel takes places at OIS@ASRS at the Ritz Carlton in Chicago on July 25, 2019. Participants: Emmett T. Cunningham Jr., MD, Ph.D., MPH, Senior Managing Director – Blackstone Life Sciences Michael Keyoung, MD, Ph.D., Managing Director & Head, North America –… Read More »
September 4, 2019|Steve Lenier CHICAGO – As innovation in the retina space has grown over the past quarter-century, so has the need for capital to finance those activities. One way innovators are meeting that need is by entering into partnerships with ex-US entities, one of many issues explored by a panel session on financing retina… Read More »
OPT-302 Combination Therapy Demonstrated Superiority in Visual Acuity over Lucentis® The primary outcome achieved: OPT-302 + Lucentis (ranibizumab) combination therapy demonstrated a statistically significant vision benefit compared to Lucentis in wet AMD patients at 24 weeks in a trial of 366 patients Intravitreal OPT-302 combination therapy was well tolerated with a safety profile similar to… Read More »
Presented in part at: 15th Annual Angiogenesis, Exudation, and Degeneration meeting, February 2018, Miami, Florida; 41st Annual Macula Society Meeting, February 2018, Beverly Hills, California; Association for Research in Vision and Ophthalmology Annual Meeting, April–May 2018, Honolulu, Hawaii; Royal College of Ophthalmologists Annual Congress 2018, May 2018, Liverpool, United Kingdom; 36th World Ophthalmology Congress, June… Read More »
